Autoglaserei

Wir bieten Ihnen Glasscheiben in allen Variationen und Tönungen aller gängigen Baujahre an.

Eintrag vom: 15.02.2013.

Whether combining nintedanib and pirfenidone is safe and tolerable in real-world setting is poorly known. We conducted a multicentre retrospective study of patients with IPF or PPF who had received a combination of nintedanib and pirfenidone and primarily assessed safety and tolerability.

 

La dose raccomandata è 150 mg di nintedanib due volte al giorno somministrati a circa 12 ore di distanza. La dose da 100 mg due volte al giorno è raccomandata solo nei pazienti che non tollerano la dose da 150 mg due volte al giorno.

 

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with rapidly progressive evolution and an unfavorable outcome. Nintedanib (NTD) is an antifibrotic drug that has been shown to be effective in slowing down the progression of the disease.

 

Prove di efficacia disponibili per nintedanib nel trattamento delle malattie interstiziali polmonari (ILD) fibrosanti croniche con fenotipo progressivo in pazienti adulti.

 

Clinical trial evidence shows that nintedanib slows the decrease of lung function compared with placebo in people with idiopathic pulmonary fibrosis with an FVC above 80% predicted. Also long-term evidence suggests that the effect of nintedanib is maintained over time.

 

A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.

 

In this double-blind placebo-controlled phase 3 trial conducted in 15 countries we randomly assigned patients with fibrosing lung disease affecting more than 10% of lung volume on...

 

This study aims to compare IPF and PPF regarding phenotype radiological patterns comorbidities prognostic factors and response to nintedanib focusing on identifying the patient subsets most likely to benefit.

 

Two groups (under nintedanib or pirfenidone) were analyzed at diagnosis through their clinical features and radiological patterns. Lung function was assessed at diagnosis (time 0) and after 6 12 and 24 months of treatment.

 

Limited data exists on the long-term comparative efficacy and tolerability of pirfenidone and nintedanib the two approved treatments for idiopathic pulmonary fibrosis (IPF). We retrospectively enrolled IPF patients treated with either pirfenidone or nintedanib at our centre between 2017 and 2023.